The US researchers at the Baylor College of Medicine, Texas Children’s Hospital have said the follow-up observations mark the ...

Poor physical performance in patients with non-Hodgkin lymphoma receiving CAR T-cell therapy was linked to worse survival and ...

Think of it this way — the human body is a kingdom which is healthy, prosperous and functions peacefully. Every once in a while, invaders from the pat ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

The Penn physician-researcher has received more funding to advance his 'Trojan horse' for attacking gastroesophageal cancer.

Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative precision diagnostics and laboratory services, announced today that it has received a Notice of Allowance ...

GloboCare has received a Notice of Allowance from the China National Intellectual Property Administration for its patent ...

The FDA has accepted an investigational new drug application for ALLO-329, an allogeneic chimeric antigen receptor T-cell ...

Some New York doctors are working on new ways to treat advanced cancers. Chimeric Antigen Receptor, or CAR, T-cell therapy treats certain blood cancers by genetically modifying a person’s T-cells to ...

TG Therapeutics will use MaxCyte’s technology to advance toward a clinical trial its azer-cel CAR T-cell therapy for ...

A patient has achieved over 18 years of remission from neuroblastoma, a type of nerve cell cancer, following treatment with ...

An 18-year survivor of neuroblastoma, a solid childhood tumor that develops in immature nerve cells, is believed to represent ...